Source: MarketScreener

Soligenix: Soligenix Announces Publication Demonstrating Thermostabilization of Filovirus Vaccine Antigens

(marketscreener.com) PRINCETON, N.J., Sept. 15, 2020 /PRNewswire/ -- Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of nonclinical results characterizing filovirus protein antigens and their...https://www.marketscreener.com/news/latest/Soligenix-Announces-Publication-Demonstrating-Thermostabilization-of-Filovirus-Vaccine-Antigens--31296954/?utm_medium=RSS&utm_content=20200915

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Christopher J. Schaber's photo - President & CEO of Soligenix

President & CEO

Christopher J. Schaber

CEO Approval Rating

68/100

Soligenix develops and commercializes biotherapeutics for the treatment of gastrointestinal disorders, inflammation and oncology diseases. Read more